Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 540.00
Bid: 548.00
Ask: 549.00
Change: 2.00 (0.37%)
Spread: 1.00 (0.182%)
Open: 527.00
High: 548.00
Low: 527.00
Prev. Close: 538.00
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AUM Update

12 Jan 2017 07:00

RNS Number : 9517T
Polar Capital Holdings PLC
12 January 2017
 

12 January 2017

Polar Capital Holdings plc

AUM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the boutique investment management group, today provides its regular quarterly update of its unaudited statement of its Assets under Management ("AUM").

 

Group AUM (unaudited)

 

Polar Capital reports that as at 31 December 2016 its AUM were £8.4bn compared to £7.3bn at the end of March 2016.

 

AUM movement in

nine months to

31 December 2016

USD

GBP

Long only

Funds

Alternative funds

Total

Long only

funds

Alternative funds

Total

AUM at

31 March 2016

$9,378m

$1,054m

$10,432m

£6,531m

£734m

£7,265m

Net subscriptions

/ (redemptions)

$(722)m

$56m

$(666)m

£(493)m

£45m

£(448)m

Market movement

and performance

$653m

$(45)m

$608m

£1,506m

£84m

£1,590m

Total AUM at

31 December 2016

$9,309m

$1,065m

$10,374m

£7,544m

£863m

£8,407m

 

Comment

 

In mid-December we released our interim results and at the time provided guidance that the US election result in November had triggered a noticeable change in flows into our funds. December has continued in the same vein that November finished and it is pleasing to report that more than £100m of net inflows were received in the month into our products, giving a total net flow for the quarter of over £300m.

 

On a less positive note the performance fees earned in the year were below the level of last year although this was the 16th consecutive year that such fees have been earned.

 

Whilst this was not our best year in terms of overall investment performance, our medium and longer term performance numbers on our UCITS products remain extremely strong, as shown in the table below. Thirteen of our eighteen Lipper rated UCITS funds are top quartile since launch, eight of which are top decile, whilst the other five funds are second quartile (as at 31 December 2016).

 

1 year

3 years

5 years

Since

inception

1st quartile

7 funds

8 funds

6 funds

13 funds

2nd quartile

5 funds

2 funds

2 funds

5 funds

3rd quartile

6 funds

3 funds

1 fund

0 funds

4th quartile

0 funds

1 fund

1 fund

0 funds

 

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fees (after the deduction of staff interests) earned and accrued in the first nine months of the Group's financial year.

 

Performance fees

net of staff allocations

Nine months to

31 Dec 15

Year to

31 Mar 16

(year-end)

Nine months to

31 Dec 16

Received

£3.0m

£3.0m

£1.1m

Accrued but not yet earned in funds with year ends on or before the financial year end

-

-

-

Total net performance fees

£3.0m

£3.0m

£1.1m

 

 

 

For further information please contact:

 

Polar Capital

Tim Woolley (CEO)John Mansell (COO)

+44 (0)20 7227 2700

Canaccord Genuity - Nomad and Joint Broker

Simon Bridges (QE)

Andrew Buchanan

Kit Stephenson

+44 (0)20 7523 8000

 

Peel Hunt - Joint Broker

Guy Wiehahn

+44 (0)20 7418 8893

Camarco

Ed Gascoigne-Pees

 

+44 (0)20 3757 4984

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDEAXFFFFDXEFF
Date   Source Headline
26th Apr 202410:33 amRNSForm 8.3 - RENALYTIX PLC
17th Apr 20243:55 pmRNSDirector/PDMR Shareholding
12th Apr 20245:43 pmRNSHolding(s) in Company
11th Apr 20247:00 amRNSAuM Update
9th Apr 20244:01 pmRNSChange of Company Secretary
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
7th Mar 20244:30 pmRNSHolding(s) in Company
6th Mar 20245:47 pmRNSForm 8.3 - DIRECT LINE INSURANCE GROUP PLC
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
27th Feb 20242:19 pmRNSForm 8.3 - Wincanton PLC
7th Feb 20242:09 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBlock listing Interim Review
25th Jan 20244:53 pmRNSForm 8.3 -Wincanton PLC
11th Jan 20247:00 amRNSAuM Update
10th Jan 20242:54 pmRNSHolding(s) in Company
10th Jan 20242:51 pmRNSHolding(s) in Company
20th Nov 20237:00 amRNSPolar Capital Holdings Unaudited interim results
9th Nov 20237:00 amRNSInvestor Presentation covering Interim Results
26th Oct 20237:00 amRNSNotice of Interim Results
12th Oct 20237:00 amRNSAuM Update
28th Sep 20235:36 pmRNSResult of AGM
18th Aug 20234:45 pmRNSDirector/PDMR Shareholding
1st Aug 202312:05 pmRNSBlock listing Interim Review
19th Jul 20234:34 pmRNSDirector/PDMR Shareholding
18th Jul 20234:30 pmRNSDirector/PDMR Shareholding
13th Jul 202311:01 amRNSDirector/PDMR Shareholding - Replacement
13th Jul 202310:48 amRNSDirector/PDMR Shareholding
13th Jul 202310:31 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAuM Update
26th Jun 20233:34 pmRNSInvestor Presentation covering Full Year Results
26th Jun 20237:00 amRNSGroup Audited Results for year ended 31 March 2023
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 202312:26 pmRNSIssue of Equity
10th May 20233:10 pmRNSDirector/PDMR Shareholding
21st Apr 20232:36 pmRNSHolding(s) in Company
14th Apr 20234:01 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSAuM Update
31st Mar 202312:23 pmRNSDirector/PDMR Shareholding
10th Mar 20233:17 pmRNSDirector/PDMR Shareholding
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
16th Feb 20235:06 pmRNSDirector/PDMR Shareholding
7th Feb 202311:09 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBlock listing Interim Review
12th Jan 20237:00 amRNSAuM Update
30th Dec 20227:00 amRNSDirectorate Change
21st Nov 20227:00 amRNSUnaudited interim results
15th Nov 20227:00 amRNSInvestor Presentation covering Interim Results
24th Oct 20227:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.